Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Chick-fil-A Access Chick-fil-A will remain open and accessible during renovations
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Lilly states that retatrutide has not been approved by any regulatory agency and should not be used outside a Lilly-sponsored clinical trial
Patients considering this pathway should ask their prospective provider directly: what is your protocol for monitoring and preserving lean mass during weight loss
US$ 21.15
US$ 26.19
US$ 29.79
US$ 21.74
